Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: LYRICA

Summary for Tradename: LYRICA

Suppliers: see list5
2013 Sales:$2,415,254,000
patent expirations by year for

Clinical Trials for: LYRICA

Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients
Status: Completed Condition: Post-operative Pain

A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy
Status: Completed Condition: Diabetic Neuropathy

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome
Status: Recruiting Condition: Irritable Bowel Syndrome

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
Status: Terminated Condition: Epilepsies, Partial

Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)
Status: Enrolling by invitation Condition: Neuralgia

Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)
Status: Enrolling by invitation Condition: Neuropathic Pain

A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder
Status: Recruiting Condition: Obsessive-Compulsive Disorder

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
Status: Completed Condition: Diabetic Neuropathy, Painful

Bioequivalence Study of Two Formulations of Pregabalin Capsules 150 mg
Status: Completed Condition: Healthy

Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement
Status: Completed Condition: PAIN

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism
CAPSULE;ORAL021446Dec 30, 2004RXNo<disabled><disabled>
Pf Prism
CAPSULE;ORAL021446Dec 30, 2004RXNo5,563,175<disabled><disabled>
Pf Prism
CAPSULE;ORAL021446Dec 30, 2004RXNo6,001,876<disabled>Y<disabled>
Pf Prism
CAPSULE;ORAL021446Dec 30, 2004RXNo6,197,819<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LYRICA

Drugname Dosage Strength RLD Submissiondate
pregabalinOral Solution20 mg/mLLyrica5/19/2010
pregabalinCapsules25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mgLyrica12/30/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology